Screener
Royalty Pharma RPRX Noncontrolling interests in subsidiaries
Noncontrolling interests in subsidiaries at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Class R redeemable shares, £1 par value; issued and outstanding: 2026–50 and 2025–50 | 63 | 63 |
| Deferred shares, $0.000001 par value; issued and outstanding: 2026–430,189 and 2025–411,475 | — | — |
| Additional paid-in capital | 4,376,266 | 4,123,088 |
| Retained earnings | 2,459,089 | 2,356,318 |
| Non-controlling interests | 2,952,975 | 3,238,039 |
| Treasury interests | (2,724) | (2,612) |
| Total shareholders’ equity | 9,785,714 | 9,714,939 |
| Total liabilities and shareholders’ equity | $19,819,771 | $19,620,780 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's noncontrolling interests in subsidiaries?
- Royalty Pharma (RPRX) reported noncontrolling interests in subsidiaries of $2.95B in Q2 2026.
- How has Royalty Pharma's noncontrolling interests in subsidiaries changed year-over-year?
- Royalty Pharma's noncontrolling interests in subsidiaries decreased by 6.4% year-over-year, from $3.16B to $2.95B.
- What is the long-term trend for Royalty Pharma's noncontrolling interests in subsidiaries?
- Over 5 years (2020 to 2025), Royalty Pharma's noncontrolling interests in subsidiaries has grown at a -8.6% compound annual growth rate (CAGR), from $5.08B to $3.24B.
- What does noncontrolling interests in subsidiaries mean?
- This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.
Ask your AI about Royalty Pharma's noncontrolling interests in subsidiaries.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude